Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

React to this article
Latest news on GILEAD SCIENCES, INC.
05:44p GILEAD SCIENCES : to Release Second Quarter 2015 Financial Results on Tuesday, J..
05:38p GILEAD SCIENCES : Announces Phase 3 Results From the First Study to Evaluate Swi..
05:17p GILEAD SCIENCES : Patent Issued for Process for Preparing an A2A-Adenosine Recep..
04:28p Yelp, Twitter, Cytec, Gilead and CNH Industrial are big market movers
11:31a GILEAD SCIENCES : US stocks move higher in early trading; investors wait for Fed..
08:46aDJStocks Gain After Fed Statement
07/28DJExpress Scripts Raises Guidance as Earnings Top Views
07/28 GILEAD SCIENCES : beats Street 2Q forecasts on surge in sales, profit
07/28DJExpress Scripts Raises Guidance as Earnings Top Views
07/28DJGilead Sales Soar on Hepatitis Drugs
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials